# NCT06492005 (NCT06492005)

> A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06492005
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Conditions: Triple-Negative Breast Cancer
- Interventions: 9MW2821; PD-1 inhibitior
- Enrollment: 160
- Primary outcome: Objective Response Rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06492005